|Bid||0.00 x 3100|
|Ask||0.00 x 1200|
|Day's Range||9.40 - 9.81|
|52 Week Range||6.26 - 24.45|
|Beta (3Y Monthly)||1.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.71|
The big shareholder groups in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to haveRead More...
BRISBANE, Calif. , March 12, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, announced today the appointment of Jason Fontenot , Ph.D., as Senior Vice President, ...
BRISBANE, Calif., March 8, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, announced today the publication in Nature Communications of improvements to its zinc finger nuclease (ZFN) platform technology, which yield a 64-fold increase in the diversity of ZFNs available for targeting any DNA segment. ZFN technology is an engineerable gene editing platform that is currently being evaluated in clinical trials for Mucopolysaccharidosis Type I (MPS I), MPS II, hemophilia B, beta thalassemia and sickle cell disease.
BRISBANE, Calif., March 6, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in the following healthcare investor ...
Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time BRISBANE, Calif. , Feb. 28, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth ...
BRISBANE, Calif., Feb. 21, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company will release its fourth quarter and full year 2018 ...
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Feb. 21, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
BRISBANE, Calif., Feb. 20, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for ST-920, a gene therapy candidate being evaluated for the treatment of adults with Fabry disease. Current standard of care for this rare, progressive condition involves regular lifelong infusions of enzyme replacement therapy (ERT). "The FDA's acceptance of the IND to evaluate ST-920 in Fabry disease enables the initiation of our third clinical development program focused on rare metabolic diseases, and our sixth active clinical program," said Edward Conner, M.D., Chief Medical Officer at Sangamo.
On Sangamo (SGMO) Q4 conference call, investors will look into genome editing development and gene regulation technology platform, used for inventing genomic therapies to address unmet medical needs.
Below are several biotech companies in the news you should know HENDERSON, NV / ACCESSWIRE / February 12, 2019 / One you should research right away, BioRestorative Therapies, Inc. (BRTX) , a life sciences ...
The following are top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 7.) Array Biopharma Inc (NASDAQ: ARRY ) Down In The Dumps (Biotech ...
Sangamo's zinc finger nucleases are competing with another technology, known as CRISPR, to show which one is most accurate and efficient in snipping genes and replacing the cut-out section with a correct version.
Sangamo said SB-318 zinc finger nuclease, or ZFN, which is being evaluated in a Phase 1/2 study dubbed EMPOWERS in patients with mild mucopolysaccharides Type 1, or MPS 1, receiving weekly enzyme replacement therapy, or ERT, suggested a dose-dependent increase in leukocyte alpha-L-iduronidase, or IDUA, enzyme activity. Plasma IDUA activity was unchanged from the baseline in all three patients studied, while baseline urine GAG measurements were at or slightly above normal.
Scientists think they have achieved the first gene editing inside the body, altering DNA in adults to try to treat a disease, although it's too soon to know if this will help.